[Case report of a complete regression of para-aortic lymph node metastasis from bladder cancer by oral administration of UFT].
We report a case in which para-aortic lymphnode metastasis from bladder cancer regressed completely by administration of UFT. The patient was a 72-year-old male who had undergone a total cystectomy for bladder cancer. Since para-aortic node metastasis was recognized in abdominal CT 1 year after the operation, we treated this patient by oral administration of UFT at a dose of 600 mg per day, and the metastatic lesion regressed completely 2 months later. After the complete regression, UFT was administered for one year. At present, 6 months after the discontinuation of UFT, para-aortic lymphnode swelling is not observed. Although adverse effects such as pigmentation and nail degeneration was found, there was no abnormal finding in blood analysis and chemistry. It is suggested that UFT may be effectively used for bladder cancer.
Nakano
E
E
Dept. of Urology, Osaka University Hospital.
Iwasaki
A
A
Seguchi
T
T
Sugao
H
H
Yoshioka
T
T
Tada
Y
Y
Matsuda
M
M
Sonoda
T
T
D000284:Administration, Oral; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000556:secondary*; D006801:Humans; D008207:Lymphatic Metastasis / Q000188:drug therapy*; D008297:Male; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use; D014498:Uracil / Q000008:administration & dosage / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology
D005641:Tegafur; D014498:Uracil